Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > AUG 24 AGM cancelled

<< Previous

Bullboard Posts

Next >>

Comment by MetzGERon Aug 20, 2022 5:29am

92 Views

Post# 34908990

RE:RE:RE:RE:RE:AUG 24 AGM cancelled

Ingiboy it is now the Perfect point to invest and to speculate.

if Replicel announces the Shiseido Deal or the commercialization of the dermaprecise then the Stock Price is at 5-10$ - After that it is to Late to invest.

if you Want to take the rocket you have to invest now if you Want to take the bulker ship then invest After all unknowns Are cleared

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario